• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study.

作者信息

Jonas Brian A, DiNardo Courtney, Fracchiolla Nicola, Pristupa Alexander, Ishizawa Kenichi, Jin Jie, Konopleva Marina, Ofran Yishai, Montesinos Pau, Kovacsovics Tibor, Jang Jun-Ho, Kantarjian Hagop, Duan Yinghui, Potluri Jalaja, Werner Michael, Pratz Keith W

机构信息

Division of Hematology and Oncology, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, California, USA.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

出版信息

Am J Hematol. 2022 Nov;97(11):E422-E425. doi: 10.1002/ajh.26707. Epub 2022 Sep 16.

DOI:10.1002/ajh.26707
PMID:36053878
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10286746/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c189/10286746/5ae121ba5257/AJH-97-E422-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c189/10286746/5ae121ba5257/AJH-97-E422-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c189/10286746/5ae121ba5257/AJH-97-E422-g001.jpg

相似文献

1
Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study.VIALE-A研究中CYP3A抑制剂的使用及其对接受维奈克拉联合阿扎胞苷治疗的急性髓系白血病患者结局的影响。
Am J Hematol. 2022 Nov;97(11):E422-E425. doi: 10.1002/ajh.26707. Epub 2022 Sep 16.
2
Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.VIALE-A研究中接受维奈克拉和阿扎胞苷治疗的急性髓系白血病患者缓解后血细胞减少的管理
Am J Hematol. 2022 Nov;97(11):E416-E419. doi: 10.1002/ajh.26692. Epub 2022 Sep 16.
3
[Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].维奈托克联合阿扎胞苷治疗老年急性髓系白血病或髓系肉瘤：三例报告及文献综述
Zhonghua Xue Ye Xue Za Zhi. 2020 Aug 14;41(8):694-696. doi: 10.3760/cma.j.issn.0253-2727.2020.08.016.
4
Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.维奈克拉与阿扎胞苷联合用药是复发/难治性急性髓系白血病患者移植策略的有效过渡方案。
Ann Hematol. 2021 Apr;100(4):1111-1113. doi: 10.1007/s00277-020-04333-7. Epub 2020 Nov 11.
5
Venetoclax plus azacitidine and LDAC induced high response rates in acute myeloid leukaemia in routine clinical practice.在常规临床实践中，维奈克拉联合阿扎胞苷及低剂量阿糖胞苷在急性髓系白血病中诱导出了高缓解率。
Br J Haematol. 2023 Jun;201(5):995-999. doi: 10.1111/bjh.18788. Epub 2023 Mar 31.
6
Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study.维奈托克联合阿扎胞苷作为晚期急性髓系白血病患者挽救治疗的疗效及预测因素：一项多中心回顾性研究
Leuk Res. 2020 Apr;91:106317. doi: 10.1016/j.leukres.2020.106317. Epub 2020 Feb 14.
7
[Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].维奈克拉与阿扎胞苷治疗难治性和复发性急性髓系白血病的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2021 Oct 14;42(10):861-864. doi: 10.3760/cma.j.issn.0253-2727.2021.10.012.
8
Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.维奈克拉联合阿扎胞苷和供者淋巴细胞输注治疗异基因造血干细胞移植后复发的急性髓系白血病患者。
Ann Hematol. 2022 Jan;101(1):119-130. doi: 10.1007/s00277-021-04674-x. Epub 2021 Sep 27.
9
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。
Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.
10
Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax.接受阿扎胞苷和维奈克拉治疗的复发/难治性白血病儿科患者的临床反应
Haematologica. 2023 Nov 1;108(11):3142-3147. doi: 10.3324/haematol.2022.282637.

引用本文的文献

1
Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center study.维奈克拉与阿扎胞苷在中国治疗急性髓系白血病的疗效及安全性：一项真实世界单中心研究
BMC Cancer. 2025 Jun 3;25(1):990. doi: 10.1186/s12885-025-14167-z.
2
Real-World Experience with Venetoclax Treatment for Newly-Diagnosed Acute Myeloid Leukemia in Japan (VENUS Study): An Interim Analysis Focusing on Neutropenia Management.日本维奈托克治疗新诊断急性髓系白血病的真实世界经验（VENUS研究）：以中性粒细胞减少症管理为重点的中期分析
Oncol Ther. 2025 Mar 7. doi: 10.1007/s40487-025-00329-3.
3
Increased trough concentration of venetoclax when combined with itraconazole for acute myeloid leukemia.

本文引用的文献

1
Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy.初治且不适合强化化疗的急性髓系白血病患者中，venetoclax 的暴露-疗效和暴露-安全性关系。
Hematol Oncol. 2022 Apr;40(2):269-279. doi: 10.1002/hon.2964. Epub 2022 Feb 9.
2
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.阿扎胞苷和维奈托克治疗未经治急性髓系白血病。
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.
3
Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
伏立康唑联合 venetoclax 用于治疗急性髓系白血病时，伏立康唑的谷浓度增加。
Ann Hematol. 2024 Nov;103(11):4497-4502. doi: 10.1007/s00277-024-05845-2. Epub 2024 Sep 27.
4
Triazole antifungal drug interactions-practical considerations for excellent prescribing.三氮唑类抗真菌药物相互作用——优秀处方的实用考虑因素。
J Antimicrob Chemother. 2024 Jun 3;79(6):1203-1217. doi: 10.1093/jac/dkae103.
5
Meta‑analysis of the efficacy of venetoclax and azacitidine combination therapy and azacitidine monotherapy for treating acute myeloid leukemia.维奈克拉与阿扎胞苷联合疗法及阿扎胞苷单药疗法治疗急性髓系白血病疗效的Meta分析
Exp Ther Med. 2024 Feb 26;27(4):164. doi: 10.3892/etm.2024.12452. eCollection 2024 Apr.
6
Real-Life Multicenter Experience of Venetoclax in Combination with Hypomethylating Agents in Previously Untreated Adult Patients with Acute Myeloid Leukemia in Greece.维奈托克联合去甲基化药物治疗希腊既往未治疗的成年急性髓系白血病患者的真实世界多中心经验
J Clin Med. 2024 Jan 19;13(2):584. doi: 10.3390/jcm13020584.
7
Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers.靶向 Venetoclax 治疗 t(11;14)多发性骨髓瘤：来自七个匈牙利中心的真实世界数据。
Pathol Oncol Res. 2022 Feb 28;28:1610276. doi: 10.3389/pore.2022.1610276. eCollection 2022.
使用基于生理的药代动力学模型对CYP3A抑制剂和诱导剂对维奈托克药代动力学的影响进行定量预测。
J Clin Pharmacol. 2017 Jun;57(6):796-804. doi: 10.1002/jcph.858. Epub 2017 Jan 4.
4
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.成人急性髓系白血病的诊断与管理：2017年国际专家小组的欧洲白血病网络（ELN）建议
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.
5
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.泊沙康唑与氟康唑或伊曲康唑对中性粒细胞减少患者的预防作用比较
N Engl J Med. 2007 Jan 25;356(4):348-59. doi: 10.1056/NEJMoa061094.
6
Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia.左氧氟沙星预防癌症和中性粒细胞减少患者的细菌感染。
N Engl J Med. 2005 Sep 8;353(10):977-87. doi: 10.1056/NEJMoa044097.